Skip to content
value.today

Treeline Biosciences, Inc.

🇺🇸 Stamford, Connecticut, USABiotechnologyFounded 2021

Formerly JHB Explorations, Inc.

Total raised
$1.1 B
4 rounds on record
Latest round
$200 M
Aug 2025
First round on record
Apr 2021
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Treeline Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2025$200 MNo. 4$50 to $250 million

Treeline Biosciences, Inc.: Raise no. 4, Aug 2025

Investors in this round

22 investors had bought by the notice of Sep 4, 2025: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$200 M of $250 M offered; $50 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey H. Engelman · Executive Officer, Director, Promoter
  • Joshua H. Bilenker · Executive Officer, Director, Promoter
  • Aftab H. Kherani · Director
  • Ali H. Satvat · Director
  • Avi H. Naider · Director
  • David H. Bonita · Director
  • David H. Schenkein · Director
  • Kristina H. Burow · Director
  • Steven H. Elms · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joshua H. Bilenker, M.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 4, 2025. Read the notice at the SEC.

equity, optionsSEC
Oct 2024$422 MNo. 3$250 million to $1 billion

Treeline Biosciences, Inc.: Raise no. 3, Oct 2024

Investors in this round

43 investors had bought by the notice of Oct 17, 2024: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$422 M of $422 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey H. Engelman · Executive Officer, Director, Promoter
  • Joshua H. Bilenker · Executive Officer, Director, Promoter
  • Aftab H. Kherani · Director
  • Ali H. Satvat · Director
  • Avi H. Naider · Director
  • David H. Bonita · Director
  • David H. Schenkein · Director
  • Kristina H. Burow · Director
  • Steven H. Elms · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joshua H. Bilenker, M.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 17, 2024. Read the notice at the SEC.

equitySEC
Sep 2022$261 MNo. 2$250 million to $1 billion

Treeline Biosciences, Inc.: Raise no. 2, Sep 2022

Investors in this round

44 investors had bought by the notice of Oct 11, 2022: 44 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$261 M of $269 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey H. Engelman · Executive Officer, Director, Promoter
  • Joshua H. Bilenker · Executive Officer, Director, Promoter
  • Aftab H. Kherani · Director
  • Ali H. Satvat · Director
  • Avi H. Naider · Director
  • David H. Bonita · Director
  • David H. Schenkein · Director
  • Kristina H. Burow · Director
  • Steven H. Elms · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joshua H. Bilenker, M.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 11, 2022. Read the notice at the SEC.

equitySEC
Apr 2021$212 MNo. 1$50 to $250 million

Treeline Biosciences, Inc.: Raise no. 1, Apr 2021

Investors in this round

34 investors had bought by the notice of Apr 30, 2021: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$212 M of $220 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey H. Engelman · Executive Officer, Director, Promoter
  • Joshua H. Bilenker · Executive Officer, Director, Promoter
  • Aftab H. Kherani · Director
  • Avi H. Naider · Director
  • David H. Bonita · Director
  • David H. Schenkein · Director
  • Kristina H. Burow · Director
  • Steven H. Elms · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joshua H. Bilenker, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 30, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Treeline Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2025).

    SEC Form D · Sep 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2025

That is all the official record says: Treeline Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Treeline Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 44 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Treeline Biosciences, Inc.
NameRoleNamed in
Jeffrey H. EngelmanExecutive officerSep 2025
Joshua H. BilenkerExecutive officerSep 2025
Aftab H. KheraniDirectorSep 2025
Ali H. SatvatDirectorSep 2025
Avi H. NaiderDirectorSep 2025
David H. BonitaDirectorSep 2025
David H. SchenkeinDirectorSep 2025
Jeffrey H. EngelmanDirectorSep 2025
Joshua H. BilenkerDirectorSep 2025
Kristina H. BurowDirectorSep 2025
Steven H. ElmsDirectorSep 2025
Jeffrey H. EngelmanPromoterSep 2025
Joshua H. BilenkerPromoterSep 2025